ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2012
Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- ESR/ERS white paper on lung cancer screening.European radiology · 2015Guideline
- Sensitivity and specificity of computed tomography hypodense sign when differentiating pulmonary inflammatory and malignant mass-like lesions.Quantitative imaging in medicine and surgery · 2022Article
- The impact of the lung EDRN-CVC on Phase 1, 2, & 3 biomarker validation studies.Cancer biomarkers : section A of Disease markers · 2022Article
- A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer.Translational research : the journal of laboratory and clinical medicine · 2021Article
- Noninvasive biomarkers for lung cancer diagnosis, where do we stand?Journal of thoracic disease · 2020Review
- Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung.BMC cancer · 2019Article
- Detection of early lung cancer among military personnel (DECAMP) consortium: study protocols.BMC pulmonary medicine · 2019Article
- Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2019Review
- Global Epidemiology of Lung Cancer.Annals of global health · 2019Review
- The Airway Transcriptome as a Biomarker for Early Lung Cancer Detection.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Review
- Complement C4d-specific antibodies for the diagnosis of lung cancer.Oncotarget · 2018Article
- AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future.American journal of respiratory and critical care medicine · 2017Review
- Assessment of the cancer risk factors of solitary pulmonary nodules.Oncotarget · 2017Article
- Clinical validation of a blood-based classifier for diagnostic evaluation of asymptomatic individuals with pulmonary nodules.Clinical proteomics · 2017Article
- Article
- Lung cancer risk test trial: study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository.BMC pulmonary medicine · 2016Article
- Carbonic anhydrase 1 is a promising biomarker for early detection of non-small cell lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Management of Pulmonary Nodules by Community Pulmonologists: A Multicenter Observational Study.Chest · 2015Observational
- Establishment of a mathematic model for predicting malignancy in solitary pulmonary nodules.Journal of thoracic disease · 2015Article
- ESR/ERS white paper on lung cancer screening.The European respiratory journal · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundCurrent management of lung nodules is complicated by nontherapeutic resections and missed chances for cure. We hypothesized that a serum proteomic signature may add diagnostic information beyond that provided by combined clinical and radiographic data.
methodsCohort A included 265 and cohort B 114 patients. Using multivariable logistic regression analysis we calculated the area under the receiver operating characteristic curve (AUC) and quantified the added value of a previously described serum proteomic signature beyond clinical and radiographic risk factors for predicting lung cancer using the integration discrimination improvement (IDI) index.
resultsThe average computed tomography (CT) measured nodule size in cohorts A and B was 37.83 versus 23.15 mm among patients with lung cancer and 15.82 versus 17.18 mm among those without, respectively. In cohort A, the AUC increased from 0.68 to 0.86 after adding chest CT imaging variables to the clinical results, but the proteomic signature did not provide meaningful added value. In contrast, in cohort B, the AUC improved from 0.46 with clinical data alone to 0.61 when combined with chest CT imaging data and to 0.69 after adding the proteomic signature (IDI of 20% P = 0.0003). In addition, in a subgroup of 100 nodules between 5 and 20 mm in diameter, the proteomic signature added value with an IDI of 15% (P ≤ 0.0001).
conclusionsThe results show that this serum proteomic biomarker signature may add value to the clinical and chest CT evaluation of indeterminate lung nodules. IMPACT: This study suggests a possible role of a blood biomarker in the evaluation of indeterminate lung nodules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.